Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and...
WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming...
WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.68 | -19.7955890264 | 18.59 | 19.779 | 14.73 | 4581611 | 15.60688159 | CS |
4 | -9.52 | -38.9684813754 | 24.43 | 26.22 | 14.73 | 1809429 | 19.02023936 | CS |
12 | -16.29 | -52.2115384615 | 31.2 | 35.68 | 14.73 | 1228075 | 24.65330047 | CS |
26 | -28.35 | -65.5339805825 | 43.26 | 47.45 | 14.73 | 1207141 | 31.65234243 | CS |
52 | -1.47 | -8.97435897436 | 16.38 | 47.45 | 14.73 | 1266340 | 29.67322614 | CS |
156 | 7.01 | 88.7341772152 | 7.9 | 47.45 | 4.3 | 742135 | 22.23753018 | CS |
260 | -8.54 | -36.4179104478 | 23.45 | 47.45 | 4.3 | 598589 | 21.67095017 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約